# Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus.

> PubMed lists PMID 28925668 in American family physician as Journal Article, with publication-date metadata of 2017-08-15 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28925668-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28925668-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-28925668-lixisenatide-v1.json
- Content SHA-256: `20b8f2daf7a74b592bca05fd5f39b4a4ad4584487fd0d0f6229e068f684bc5ff`

## Claims and source pins

### Headline

Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus. ([`pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b`](#source-pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b))

### Summary

PubMed lists PMID 28925668 in American family physician as Journal Article, with publication-date metadata of 2017-08-15 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b`](#source-pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b))

### Paragraph 1

PubMed lists PMID 28925668 in American family physician as Journal Article, with publication-date metadata of 2017-08-15 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b`](#source-pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b`](#source-pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b))

## Sources

<a id="source-pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b"></a>
- **Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus. · retained source version 1:2026-01-27:current:742d57981f1b6feb5dafabb69d9dcfd2255af5923c7508466b660678866d8e59** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28925668/) (`pubmed-observation-pmid-28925668-2026-01-27-742d57981f1b`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-28925668-lixisenatide-v1.json SHA-256: 20b8f2daf7a74b592bca05fd5f39b4a4ad4584487fd0d0f6229e068f684bc5ff.